Remsima turned over in market share against original medicine for first time as biosimilar
Remsima and Truxima are raising its share in the European market.
According to Celltrion Healthcare, ‘Remsima(generic name: infliximab),’ a biosimilar for the treatment of autoimmune disease, and ‘Truxima(generic name: rituximab),’ a biosimilar for the treatment of hematologic malignancies, repo...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
